Gedeon Richter receives EC approval for Esmya market relaunch
…are not eligible for surgery. Studies should be carried out to determine the effects on the liver and whether these measures effectively minimise the risks. The EMA review of the drug was launched in December 2017 after four cases of serious liver damage were observed among patients.
Sign up now to open the entire news item.You are allowed to open only one news item from PMR websites.
(to send requested information)
(required for new e-mails only)